- Home
- THFF vs ARVN Comparison
THFF vs ARVN Comparison
Compare THFF & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- ARVN
- Stock Information
- Founded
- THFF 1984
- ARVN 2015
- Country
- THFF United States
- ARVN United States
- Employees
- THFF N/A
- ARVN N/A
- Industry
- THFF Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- THFF Finance
- ARVN Health Care
- Exchange
- THFF Nasdaq
- ARVN Nasdaq
- Market Cap
- THFF 686.6M
- ARVN 676.2M
- IPO Year
- THFF N/A
- ARVN 2018
- Fundamental
- Price
- THFF $56.71
- ARVN $11.15
- Analyst Decision
- THFF Buy
- ARVN Buy
- Analyst Count
- THFF 3
- ARVN 23
- Target Price
- THFF $60.00
- ARVN $17.80
- AVG Volume (30 Days)
- THFF 65.4K
- ARVN 2.4M
- Earning Date
- THFF 10-28-2025
- ARVN 11-05-2025
- Dividend Yield
- THFF 3.63%
- ARVN N/A
- EPS Growth
- THFF 69.68
- ARVN N/A
- EPS
- THFF 6.25
- ARVN N/A
- Revenue
- THFF $245,255,000.00
- ARVN $312,300,000.00
- Revenue This Year
- THFF $32.49
- ARVN N/A
- Revenue Next Year
- THFF $3.52
- ARVN N/A
- P/E Ratio
- THFF $8.98
- ARVN N/A
- Revenue Growth
- THFF 29.00
- ARVN 93.86
- 52 Week Low
- THFF $42.05
- ARVN $5.90
- 52 Week High
- THFF $63.04
- ARVN $28.70
- Technical
- Relative Strength Index (RSI)
- THFF 59.34
- ARVN 71.34
- Support Level
- THFF $54.56
- ARVN $9.27
- Resistance Level
- THFF $57.45
- ARVN $10.18
- Average True Range (ATR)
- THFF 1.58
- ARVN 0.45
- MACD
- THFF 0.43
- ARVN 0.11
- Stochastic Oscillator
- THFF 90.40
- ARVN 85.40
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.